硼替佐米联合沙利度胺、地塞米松用于多发性骨髓瘤的疗效观察  

The Evaluation on the Combination of Bortezomib,Thalidomide,Dexamethasone for the Treatment of Multiple Myeloma

作　　者：陈杰甫[1] 武永强[1] 杨淑杰[1] 唐广[1] CHEN Jiefu WU Yongqiang YANG Shujie et al.(Anyang District Hospital ,Anyang City, He＇ nan Province 45500)

机构地区：[1]安阳地区医院,河南省安阳市455000

出　　处：《医学理论与实践》2017年第4期479-481,共3页The Journal of Medical Theory and Practice

摘　　要：目的:研究硼替佐米联合沙利度胺、地塞米松用于多发性骨髓瘤患者的临床治疗效果。方法:30例多发性骨髓瘤患者,给予硼替佐米+沙利度胺+地塞米松方案治疗,于治疗前、后测定患者的血M蛋白和血β2-MG含量,于治疗结束后,评价患者的反应率,询问患者的不良反应。结果:疗程结束后,患者的血M蛋白和血β2-MG含量显著低于治疗前,患者的总反应率为84.38%,不良反应情况较轻。结论:硼替佐米联合沙利度胺、地塞米松治疗多发性骨髓瘤,安全有效。Objective： To evaluate the efficacy of the combination of Bortezomib, Thalidomide, Dexamethasone for the treatment of multiple myelorna. Methods.30 patients with multiple myeloma accepted the treatment of Bortezomib, Thalidomide and Dexamethasone. The content of blood M protein and β2-MG were measured before and after the experiment. The response rates were evaluated and the adverse reactions were recorded at the end of the experiment. Results. The final content of blood M protein and β2-MG were significantly lower than that before the experiment （P〈0.05）. The total response rate was 84. 38%, and the adverse reactions were mild. Conclusion： It is safe and effective of the combination of Bortezomib,Thalidomide, Dexamethasone for the treatment of multiple myeloma.

关 键 词：硼替佐米 多发性骨髓瘤 疗效观察 

分 类 号：R739.9[医药卫生—肿瘤]